Dainippon Sumitomo Pharma Co. and Shionogi & Co. said June 5 they have entered into a license agreement to market a combination of the anti-hypertension drugs irbesartan and amlodipine besilate in Japan.
Dainippon Sumitomo said the combined drug, known as DSP-8153, had been shown in clinical trials in Japan to be effective for patients with hypertension uncontrolled by irbesartan or amlodipine besilate alone.
Masayo Tada, president and CEO of Dainippon Sumitomo, said: “I am very pleased to enter into an agreement with Shionogi, (which has) a strong sales network in Japan (and) also commercializes irbesartan. Both companies will conduct activities to provide information to medical institutions to ensure this combination product is delivered to more patients who need it.”
Dainippon Sumitomo has submitted an application for manufacturing and marketing approval to Japan’s Ministry of Health, Labor and Welfare.
- « Prev
- Next »